Embedded Files
Despite effective retinal therapy, still millions go blind every year. Our medical co-founders have demonstrated how to overcome this issue. Now, we scale their 2nd-opinion-approach globally - using AI.
Despite effective retinal therapy, still millions go blind every year. Our medical co-founders have demonstrated how to overcome this issue. Now, we scale their 2nd-opinion-approach globally - using AI.
Visual acuity outcomes over time:
theoretical possible results: RCT outcomes (phase III)
our doctors' results: outcomes from Münster "Portal" method
average doctor results: real-world outcomes e.g. AURA study
no therapy results: outcomes untreated patients
Green delta: improvement potential we try to leverage with our AI-based 2nd opinion for anti-VEGF therapy
Our History
Our History
2011: Our medical co-founders establish one of the 1st tele-ophthalmic networks worldwide (Münster "Portal") to provide 2nd opinions on retinal therapy
2014: Digital study protocol (eCRF) to monitor success
2016: One of the 1st publications on improving therapy adherence + persistence (patient compliance)
2018: Start of using AI to analyse the growing therapy data with Prof. Reiner Kurzhals
2019: Publication of 1st results in tele-ophthalmic network (Münster "Portal") of better outcomes (s. graph) and more patients remaining in therapy compared to standard-of-care
2020: Presentation at DOC of groundbreaking 2-year-outcomes of 3x better outcomes (s. graph) + 2x more patients remaining in therapy
2020: German AI award for deepeye research project
2021: Incorporation of deepeye Medical GmbH
2022: Initial publication of AI as a 2nd opinion to support retinal therapy, supported by Novartis
2022: Collaboration with University Eye Hospital of Munich (LMU), one of the largest EU eye clinic with a retinal AI research group
2023: Publication together with Bayer, transferring the prognostic AI to diverse populations, imaging machines and regimens
Core of Our Mission
Core of Our Mission
With over 100 million individuals globally facing the menace of vision-impairing retinal diseases, the urgency to act is undeniable. A significant two-thirds of blindness cases in the EU and the US are attributable to these diseases, most notably nAMD.
Our precision medicine platform is based on a clinical-proven method that elevates therapy outcomes by up to six-fold in two steps:
A leap in clinical routine visual acuity to the level of approval studies (3x).
An amplification in therapy adherence over 24 months from an average of 38% to a striking 78% (2x).
Our bold vision is to prevent 1 million people from blindness by 2030. By equipping ophthalmologists with AI-powered foresight into their patients’ futures, we are enhancing optimal therapy prognosis, while fundamentally redefining the fight against retinal diseases. Top pharma players and medical associations already harness deepeye’s AI for research purposes, unveiling new insights into therapy data. With a network of leading scientific research partners, we are on our journey to deliver therapy decision support with just a click at the point of care.
Our Experienced, International Team
Our Experienced, International Team
deepeye has become a fast-growing medical device software startup based in Munich, with a team of experts spread across Germany.
Looking for Impact in Your Job?
Looking for Impact in Your Job?
We are always looking for dedicated people with unique expertise to join the deepeye team.
Page updated
Report abuse